Faced with generic threats to its popular Effexor XR, company banking on Pristiq
(Newser) -
Antidepressant Effexor XR will soon lose patent protection, and maker Wyeth is hoping Pristiq, the successor drug approved today by the FDA, will soften the financial blow. Higher-ups at the company gush over Pristiq's advantages, including zero acclimation time and no liver interaction, and hope that sales will offset losses...
More »
